Magenta Therapeutics, Inc. (MGTA) financial statements (2022 and earlier)

Company profile

Business Address 100 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments176,926148,835145,729142,570
Cash and cash equivalents131,65058,15265,07158,345
Short-term investments45,27690,68380,65884,225
Other undisclosed current assets3,7672,6924,1142,751
Total current assets:180,693151,527149,843145,321
Noncurrent Assets
Property, plant and equipment7,4618,3129,89110,212
Restricted cash and investments1,7801,7801,7801,780
Total noncurrent assets:9,24110,09211,67111,992
TOTAL ASSETS:189,934161,619161,514157,313
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,86311,43014,11510,419
Accounts payable3,0403,7602,8123,492
Accrued liabilities7,8237,67011,3036,927
Total current liabilities:10,86311,43014,11510,419
Noncurrent Liabilities
Liabilities, other than long-term debt6,3996,2836,206 
Deferred rent credit6,3996,2836,206 
Other undisclosed noncurrent liabilities   1,246
Total noncurrent liabilities:6,3996,2836,2061,246
Total liabilities:17,26217,71320,32111,665
Stockholders' equity
Stockholders' equity attributable to parent172,672143,906141,193145,648
Common stock59493933
Additional paid in capital498,210398,311320,641248,349
Accumulated other comprehensive income (loss)(30)(23)8(8)
Accumulated deficit(325,567)(254,431)(179,495)(102,726)
Total stockholders' equity:172,672143,906141,193145,648
TOTAL LIABILITIES AND EQUITY:189,934161,619161,514157,313

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating expenses(74,692)(78,702)(82,969)(59,963)
Operating loss:(74,692)(78,702)(82,969)(59,963)
Nonoperating income (expense)(708)(179)1,0092,448
Investment income, nonoperating(708)(179)1,009190
Loss before gain (loss) on sale of properties:(75,400)(78,881)(81,960)(57,515)
Other undisclosed net income4,2643,9455,191 
Net loss attributable to parent:(71,136)(74,936)(76,769)(57,515)
Preferred stock dividends and other adjustments   (88)
Net loss available to common stockholders, diluted:(71,136)(74,936)(76,769)(57,603)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(71,136)(74,936)(76,769)(57,515)
Comprehensive loss:(71,136)(74,936)(76,769)(57,515)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(7)(31)16(8)
Comprehensive loss, net of tax, attributable to parent:(71,143)(74,967)(76,753)(57,523)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: